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Abstract
Although various parts of J. curcas (Jatropha curcas L., Euphorbiaceae) have
long been used as traditional folk medicines for their antiviral, analgesic, and/or
antidotal efficacies, we are the first to investigate the role of anti-carcinogenicity
of isoamericanol A (IAA) from the seed extract. Our results showed that IAA is
capable of inhibiting cell proliferation in a dose-dependent manner on the
human cancer cell lines of MCF-7, MDA-MB231, HuH-7, and HeLa. Flow
cytometry analysis showed IAA significantly induces cell cycle arrest at G2/M
on MCF-7 cells. At both protein and mRNA levels examined by western blot
and real-time PCR, the results revealed increased expression of BTG2
(B-cell translocation gene 2), p21 (p21WAF1/CIPI), and GADD45A (growth arrest
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and DNA-damage-inducible, alpha) after IAA treatment, but inversed expression
in CDK1 (cyclin-dependent kinase 1) and cyclins B1 and B2. All these effects
contribute to G2/M cell cycle arrest. Furthermore, these results coincide with the
changes in molecular expressions determined by DNA-microarray analysis. Our
findings indicate that IAA has an inhibitory effect on cell proliferation of
MCF-7 through cell cycle arrest, giving it great potential as a future therapeutic
reagent for cancers.
Keywords: Health sciences, Pharmaceutical science, Plant biology,
Cancer treatment, Cancer
1. Introduction
Almost all parts of J. curcas trees have long been used as traditional folk
medicine in African and Asian countries for a variety of sicknesses [1, 2]. The
latex has been used as an antibacterial agent. Apigenin, vitexin, and isovitexin
are contained in the leaves and work well against fever, rheumatic and muscular
pains, infection, and malaria [1]. Its leaves and roots are used as antidotes for
snake venom [3]. The roots also serve as treatment for sexually transmitted
diseases [2]. Its seeds are used in soap oil and biodiesel production, as well as
to fight infectious disease [3]. There are some reports that show anticancer
activity in vitro by the applications of J. curcas phorbol esters from its kernel
meal [4], and curcin from its seeds [5].
In Thailand, J. curcas seed extract is a source of oil for biodiesel energy [6, 7],
but [15_TD$DIFF]its processing involves a great amount of seed waste. It would be
worthwhile to find a medical use for residual byproducts. IAA from the seeds of
Phytolacca americana was reported to exhibit neurotrophic and antioxidant
properties [8, 9]. However, much about its medicinal potential as a cancer
treatment has not been investigated. As a goal of this study, neo-lignan IAA
((2R)-3β-(3,4-Dihydroxyphenyl)-6-[(E)-3-hydroxy-1-propenyl]-2,3-dihydro-1,4-
benzodioxin-2α-methanol, Fig 1) was tested on the cancer cell lines of MCF-7
(human breast cancer cell line), MDA-MB231 (human breast cancer cell line),
HuH-7 (human hepatocellular carcinoma cell line), and HeLa (human cervical
[(Fig._1)TD$FIG]
Fig. 1. Chemical structure of isoamericanol A.
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cancer cell line), in search of anti-carcinogenic ability. Later, we focused on the
study of molecular mechanisms of IAA treatment that cause an inhibitory effect
on MCF-7. Our findings shed light on the potential of IAA from the J. curcas
extract as a breast cancer treatment.
2. Materials and methods
2.1. Cell culture
At 37 °C under a humidified atmosphere of 5% CO2, all tested cells (MCF-7,
MDA-MB-231, HuH-7, and HeLa) were cultured in D-MEM (Sigma) with
10% heat-inactivated fetal bovine serum and 1% penicillin-streptomycin
(GE Healthcare, Buckinghamshire, UK).
2.2. IAA preparation
IAA from the residues of expeller-pressed J. curcas seeds were successfully
purified from the organic layer of the MeOH extract with a purity of over 99%
by the Department of Agriculture at Kagawa University [9, 10]. The extraction
methods from J. curcas seeds and IAA purification has been patented from the
Japan patent office [11]. However, the experiment requires a great amount of
IAA; it was mass-produced as previously described by Chen et al. [12]. To
obtain enough amount of IAA, IAA was synthesized from radical coupling
reaction of caffeyl alcohol with silver carbonate [12].
IAA stock of a 10 mg/ml IAA concentration was prepared in 100% pure
dimethyl sulfoxide (DMSO, Sigma, St. Louis, MO, USA). It was later diluted
with D-MEM to prepare 0, 25, 50, and 100 μg/ml IAA solutions. 1% DMSO
was maintained for all different concentrations of tested IAA medium (0, 25, 50,
and 100 μg/ml). These solutions were then filtered with a 0.45 μm filter syringe.
2.3. Cell proliferation assay
MCF-7 and HuH-7, MDA-MB-231, and HeLa were cultured in 96-well plates
for up to four days. The concentrations of IAA tested were 0, 25, 50, and 100
μg/ml for cell proliferation assays. Cancer cell proliferation rate was studied
using Cell Counting Kit-8 (Dojindo, Kumamoto, Japan). This kit uses WST-8,
a water-soluble tetrazolium salt, as a coloring agent.
Cellular dehydrogenases reduces WST-8 [2-(2-methoxy-4-nitrophenyl)-3-(4-
nitrophenyl)-5-(2,4-disulfophenyl)-2H-tetrazolium, monosodium salt], which
yields orange colored formazan. The total number of cells that exist in each well
is directly proportionate to the amount of the formazan produced by enzymes in
the cell. The cell count is then translated to absorbance values. The absorbance
measurements were taken at a wavelength of 450 nm with the SH-9000 Lab
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microplate reader (Corona, Ibaragi, Japan). Absorbance measurements were
taken 0, 24, 48, and 72 h after IAA treatment.
2.4. DNA microarray analysis
MCF-7 subjected to 0 and 25 μg/ml IAA treatment for three days was used for
microarray analysis. It was performed by Filgen Inc. (Nagoya, Japan) with
GeneChip® Human Gene 2.0 ST Array (Affymetrix Inc., Santa Clara, CA,
USA), containing 25 mer oligonucleotide probes. The fluorescence images of
hybridized microarrays were obtained with GeneChip® scanner 3000 7G
(Affymetrix Inc.). Scanned data were transformed into numerical values and
analyzed using Expression ConsoleTM Software (Affymetrix Inc.). The method
of Robust Multichip Array (RMA) was applied to adjust the data. Microarray
Data Analysis Tool Ver3.2 software (Filgen Inc.) was used to further classify
the data into functional subgroups.
2.5. Cell synchronization, drug treatment, and cell cycle
analysis by flow cytometry
After 24 h of cell seeding, the cells were synchronized with serum free medium
for another 24 h. The following day, additives mixed in fresh 10%
FCS-containing medium were applied. MCF-7 samples were harvested after
three days of 0 or 25 μg/ml IAA treatments. On the third day, the samples were
fixed in 70% ethanol at 4 °C for 24 h. The fixed samples were washed with
PBS and incubated in 100 μg/ml propidium iodide (Wako, Yokohama, Japan)
and 200 μg/ml RNase (Sigma) for 30 min at 37 °C in the dark. The flow
cytometric cell analysis was performed, using a Beckman Coulter Cytomics
FC500 Flow Cytometry Analyzer (Beckman Coulter, Fullerton, CA, USA).
MultiCycle AV (Phoenix Flow Systems) DNA analysis software enabled
determination of the phase of cell cycle arrest by comparing percentages of each
cell stage between the control and treatment groups (G1, S, G2/M).
2.6. TUNEL staining
MCF-7 cells were tested for occurrence of apoptosis due to 0, 25 or 50 μg/ml
IAA treatment after three days. Staurosporine (Sigma) was used as a positive
control and applied 24 h prior to fixation at a concentration of 0.1 μg /ml.
TUNEL staining was performed with the DeadEndTM Colorimetric TUNEL
System kit (Promega, Madison, WI, USA). The cells were seeded on
poly-L-lysine (Sigma) coated LAB-TEK®II (Nalge Nunc International,
Rochester, NY, USA) chamber slides. The cells were fixed and TUNEL stained
as per manufacturer's protocol (Promega). Percentages of apoptotic cells were
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quantified by manually counting cells on a well under each condition. Counting
was continued to between 2,000 to 3,000 total cells.
2.7. Western blot analysis
MCF-7 cells treated with 0 or 25 μg/ml IAA for three days were lysed and
centrifuged. The supernatant was used for western blot analysis. Proteins were
separated on a 12.5% SDS-PAGE gel and electrotransferred onto a nitrocellulose
membrane (Millipore, [16_TD$DIFF] Billerica, MA, USA). After blocking, immunoblotting was
performed using anti-BTG2 and anti-β-actin antibodies (Sigma), anti-p21 and
GADD45A antibodies (Cell Signaling Technology or CST, Danvers, MA, USA),
and anti-CDK1, cyclins B1 and cyclin B2 antibodies (Santa Cruz Biotechnology,
Inc., Santa Cruz, CA, USA). Membranes were probed with a horseradish
peroxidase-conjugated anti-rabbit or anti-mouse IgG (CST). Proteins were
detected by an enhanced chemiluminescence system (TAITEC, Saitama, Japan).
The signals were analyzed with ImageJ [13].
2.8. Quantitative real-time PCR
After three days of 0 or 25 μg/ml IAA treatments, mRNA was extracted
using RNeasy Protect Mini Kit (Qiagen). With the Omniscript® Reverse
Transcription Kit (Qiagen), the collected RNA was reverse transcribed
to cDNA. PCR was done for six target genes: BTG2, p21, GADD45A, CDK1,
and cyclins B1 and B2. As per manufacturer's protocol, the Applied
Biosystems® 7300 real-time PCR (Life TechnologiesTM, Carlsbad, CA, USA)
was performed. Beta-actin was used for normalizing data results in each
PCR reaction. The Ct values were considered to be an expression level of the
gene of interest.
2.9. Statistical analysis
Data are expressed as mean ± standard deviation (SD) from at least three
independent trials. The significance of difference between the control and
drug-treated groups was evaluated by ANOVA and/or Student's t-test, using
Microsoft Excel. Statistical significance was set at p < 0.05.
3. Results
3.1. Effect of IAA on growth of various cancer cells
MCF-7, MDA-MB-231, HuH-7, and HeLa were tested to determine the effects
of IAA. The inhibition of the growth in all tested cell lines occurred in a dose-
dependent manner at 25, 50, and 100 μg/ml IAA. The IAA inhibition became
apparent on Day 2, then definitive on Day 3 (Fig. 2). The differences between
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the control growth rate and those of the three IAA treatment groups were all
statistically significant on Day 3. Because the IAA inhibitory effect was
observed starting at a 25 μg/ml dose in the cell proliferation assay, we decided
to focus on the comparisons between this concentration of IAA and 0 μg/ml
IAA on MCF-7 for further experiments (excepting TUNEL assays, for which
both 25 μg/ml and 50 μg/ml IAA concentrations were used).
3.2. Changes in gene expressions
Microarray was used to determine the changes in genes that may occur in
MCF-7 with IAA treatment. Using Microarray Data Analysis Tool Ver3.2,
the number of genes of interest was narrowed down to 137 with a ratio
(test/control) of ≤ 0.5 and 54 genes with a ratio of ≥ 2.0, a limitation was
recommended by Filgen Inc. In support of the Gene-Ontology database, our
selected genes were categorized into three groups (Table 1): cell cycle-related,
apoptosis-related, and breast cancer-related.
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Fig. 2. Effect of IAA on a series of human cancer cell lines. MCF-7 (A), MDA-MB-231 (B),
HuH-7 (C), and HeLa (D) were used to study the effects of IAA. Cell growth inhibition was
observed in all tested cell lines in a dose-dependent manner. Each value was obtained by
an average of 4 wells ± SD (control vs IAA; **p < 0.01, ***p < 0.001).
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As Table 1 shows, among cell cycle related genes, GADD45A, BTG2, and p21
expressions were enhanced by 3.49 fold, 2.24 fold, and 2.02 fold, respectively.
On the contrary, cyclin B2 and CDK1 were reduced by 0.50 [17_TD$DIFF]fold and 0.45 fold,
respectively. As for a cyclin B2 related gene, cyclin B1 was reduced by
0.64 fold though it was not quite ranked within our set ratio change. FAS was
enhanced by 2.17 fold, but BIRC5 was decreased by 0.49 fold for apoptosis
related genes. Known breast cancer related genes, receptor for RHAMM,
SGOL1, TOP2A, BRCA2, TP73, KIAA1524, PBK, and KIF14 were also
reduced with IAA treatment.
3.3. Effect of IAA on the cell cycle progression
Because microarray analysis resulted in the indication of both cell cycle arrest
and apoptosis induced by IAA treatment, flow cytometry was used first to test if
IAA treatment interfered with MCF-7 cell growth by cell cycle arrest (Fig. 3).
From the control, 75.13 ± 2.95% of the cells were at G1 phase, compared to
47.43 ± 4.03% of the cells from 25 μg/ml IAA treatment (p < 0.001).
13.74 ± 2.35% of cells were at S phase from the control, compared
Table 1. Classification of the Candidate Genes that have changed due to 25 μg/ml
IAA treatment.
Function Gene Gene Description Ratio Flag
Cell Cycle Related GADD45A growth arrest and DNA-damage-inducible, alpha 3.49
BTG2 BTG family, member 2 2.24
CDKN1A cyclin-dependent kinase inhibitor 1A (p21, Cip1) 2.02
CCNB2 cyclin B2 0.50
CDK1 cyclin-dependent kinase 1 0.45
Apoptosis Related FAS TNF receptor superfamily, member 6 2.17
BIRC5 baculoviral IAP repeat containing 5 0.49
Breast Cancer Related HMMR hyaluronan-mediated motility receptor (RHAMM) 0.50
SGOL1 shugoshin-like 1 (S. pombe) 0.47
TOP2A topoisomerase (DNA) II alpha 170kDa 0.45
BRCA2 breast cancer 2, early onset 0.44
TP73 tumor protein p73 0.43
KIAA1524 KIAA1524 0.40
PBK PDZ binding kinase 0.39
KIF14 kinesin family member 14 0.37
As described in the materials and method section, DNA microarray analysis was performed with
GeneChip® Human Gene 2.0 ST Array (Affymetrix Inc.). With or without 3-day IAA treatment,
any changes in mRNA expression was observed using DNA microarray analysis. Values of ratio
indicates increase or decrease relative to 0 μg/ml IAA treatment.
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to 22.41 ± 3.82% from the treatment (p < 0.05). 11.14 ± 0.7% of cells were at
G2/M phase from the control, compared to 30.16 ± 1.85% from the treatment
(p < 0.001). Although there was an accumulation of cells at both S and G2/M
stages in MCF-7, the IAA treatment induced arrest mainly at the G2/M stage.
3.4. Effect of IAA on induction of apoptosis
TUNEL assay was performed to test if IAA triggered apoptosis in MCF-7 cells.
In comparison to the control, 25 and 50 μg/ml IAA treatment resulted in more
apoptotic cells (Fig. 4). The percentages of apoptotic cells from 0, 25, and
50 μg/ml IAA treatments after 72 h were 9.16 ± 5.16%, 13.04 ± 4.56% and
24.12 ± 10.97%, respectively. A significant increase of apoptotic cells compared
to the control was observed at 50 μg/ml IAA (p < 0.05), but not at 25 μg/ml
IAA. Staurosporine, a well-known apoptotic inducer, was used as the positive
control in the concentration of 0.1 μg/ml. A significantly higher percentage of
apoptotic cells (88.69 ± 10.16%, p < 0.001) were observed even at the 24 h
incubation point compared to the negative control (4.84 ± 1.92%, pictures
not shown).
3.5. Effect of IAA on cell cycle regulatory proteins
Of the molecules with a test/control ratio of ≤ 0.5 and ≥ 2.0 from microarray
results, BTG2, p21, GADD45A, CDK1, and cyclin B2 were chosen for western
blot analysis as candidates for general G2/M cell cycle arrest regulatory
molecules. Cyclin B1 was also included in this study because, similar to cyclin
B2, it is known to be a major activator of CDK1 [14, 15]. The result of our
western blot analysis agrees with previous findings [14, 15], (Fig. 5A) and the
microarray analysis of those six molecules. The results were quantified and
[(Fig._3)TD$FIG]
Fig. 3. Dynamics of cell cycle regulation. MCF-7 cells were treated for 25 μg/ml IAA application
for 3 days (control, A; 25 μg/ml IAA, B). Drug treatment induced MCF-7 (1 × 106 cells) to arrest at
the G2/M stage (control vs. IAA; *p < 0.05, ***p < 0.001).
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Fig. 4. Apoptosis detection (Scale bar: 100 μm). Dark brown coloring indicates TUNEL-positive apoptotic cells. The cells were treated with 1% DMSO (A), and 25 (B) & 50 μg/ml (C) IAA
for 3 days (control vs IAA; *p < 0.05). The cells were also treated with 0.1 μg/ml staurosporine as a positive control (D) (control vs staurosporine; ***p < 0.001). Percentages of apoptosis
induced by IAA and staurosporine are shown (E).
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exhibited by the fold changes in protein expression (Fig. 5B). With 25 μg/ml
IAA treatment, the expression of BTG2, p21, and GADD45A were 2.26 ± 0.61
fold (p < 0.05), 3.84 ± 1.48 fold (p < 0.001), and 5.54 ± 1.36 fold (p < 0.05)
higher, respectively, than the control. Contrarily, the expression of CDK1 and
cyclins B1and B2 were 0.16 ± 0.06 fold (p < 0.001), 0.31 ± 0.15 fold
(p < 0.01) and 0.25 ± 0.02 fold (p < 0.001) lower than the control, respectively.
3.6. Changes in cell cycle regulators at mRNA level
As the results showed in microarray analysis (Table 1), flow cytometry (Fig. 3),
and western blot analysis (Fig. 5) on MCF-7, real-time PCR (Fig. 6) also
verified both increased and decreased changes in expression for six of the cell
cycle regulatory proteins. Compared to the control, BTG2, p21, and GADD45A
increased by 2.52 ± 0.82 fold (p < 0.01), 6.44 ± 1.41 fold (p < 0.01), and
6.09 ± 1.38 fold (p < 0.01), respectively with IAA treatment. On the other
hand, CDK1 and cyclins B1 and B2 decreased by 0.49 ± 0.13 fold (p < 0.01),
0.66 ± 0.16 fold (p < 0.05) and 0.42 ± 0.10 fold (p < 0.001), respectively.
4. Discussion
Many plants have been widely used in traditional medicine due to their unique
properties [16]. TAXOL, a substance isolated from the bark of a Pacific yew
tree over twenty years ago [17], is still in modern use as a chemotherapy
treatment. Another natural product, IAA (Fig. 1) has been successfully extracted
[(Fig._5)TD$FIG]
Fig. 5. Changes in expressions of cell cycle regulatory proteins. BTG2, p21, and GADD45A protein
expression increased due to 25 μg/ml IAA application. On the other hand, CDK1 and cyclin B2
expression decreased in comparison to 1% DMSO control (A). Protein expressions were quantified
for ratio comparison (B), (control vs IAA; *p < 0.05, **p < 0.01, ***p < 0.001).
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from J. curcas seeds. In this experiment, we became the first to link IAA
function to possible cancer treatment. As our results show, IAA is capable of
inhibiting growth of several cancer cell lines in vitro (Fig. 2). Starting at the
concentration of 25 μg/ml, IAA exhibited its inhibitory effect on cancer cell
growth, which was statistically significant compared to the control (p < 0.05).
We further investigated the molecular mechanisms of IAA that inhibit cell
proliferation on the breast cancer cell line MCF-7. Among nearly 200 up- and
down-regulated genes (ratio ≥ 2.0 or ≤ 0.5) selected for microarray analysis,
we focused on three up-regulated genes; BTG2, p21 and GADD45A, and two
down-regulated genes; CDK1, and Cyclin B2, all of which are considered to
correlate with cell cycle regulation of the G2/M stage (Table 1). Our microarray
analysis also showed decreased expression in cyclin B1, in addition to cyclin
B2. Both were chosen for observation as G2/M cell cycle regulatory genes, in
spite of cyclin B1's reduction value falling outside of the accepted range. The
real-time PCR result of the decreasing trends for cyclin B1 and B2 matched the
microarray results, confirming that both B1 and B2 cyclins were reduced in
response to IAA treatment.
The two proteins of cyclin B1 and B2 are suggested to localize at different
places [18, 19]. Cyclin B1/CDK1 complexes can move between the cytoplasm
and nucleus, and regulate cell rounding, chromatin condensation, aster
formation, and nuclear membrane breakdown in mitotic events [18, 19]. Cyclin
B2, on the other hand, exists in the Golgi apparatus, where the complex it forms
with CDK1 is essential for the mitotic reorganization of the Golgi apparatus
[19, 20]. Because activation of cyclin B/CDK1 complex initiates entry into the
[(Fig._6)TD$FIG]
Fig. 6. Changes in mRNA expressions of cell cycle regulators. BTG2, p21, and GADD45A mRNA
expression increased due to 25 μg/ml IAA application, whereas CDK1 and cyclin B2 expression
decreased in comparison to 1% DMSO control (control vs IAA; *p < 0.05, **p < 0.01,
***p < 0.001).
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M phase, G2/M transition usually requires a functional cyclin B/CDK1 complex
[21, 22, 23]. In human breast cancer cell lines, such as MDA-MB-231 or
MCF-7, BTG2 mRNA expression is generally undetectably low [24], and it is
one of the tumor suppressor genes that inactivates the cyclin B1/CDK1 complex
[25, 26]. GADD45A and p21 bind to CDK1, resulting in dissociation of the
cyclin B/CDK1 complex and eventually induction of cell cycle arrest at G2/M
[18, 27, 28]. As clearly shown in our data of cell cycle analysis (Fig. 3),
western blot analysis (Fig. 5) and real-time PCR (Fig. 6), IAA treatment
initiated G2/M arrest on MCF-7 by the increased expression of BTG2, p21, and
GADD45A. These molecules may have caused the reduction of CDK1 activity
by dissociating the cyclin B1/CDK1 and cyclin B2/CDK1 complexes as
indicated in the scheme (Fig. 7). Interestingly, the IAA treatment also showed a
direct reducing effect on the expression of CDK1 and cyclins B1 and B2, in
addition to up-regulation of CDK1 inhibitors of BTG2, p21, and GADD45A
(Figs. 5 and 6). IAA may have induced G2/M cell cycle arrest by two
[(Fig._7)TD$FIG]
Fig. 7. Possible IAA-induced molecular mechanism on MCF-7. IAA reduces MCF-7 cell
proliferation by G2/M cell cycle arrest through stimulation of BTG2, p21, and GADD45A, along
with direct reduction of CDK1 and cyclin B1& B2 expression.
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mechanisms. The first is by the indirect CDK1/cyclin B complex inhibition
through the increased expression of CDK1 inhibitors BTG2, p21, and
GADD45A. The second is by the direct reduction/inhibition of CDK1 and
cyclin B1 and B2. Therefore, IAA has the ability to create a double threat to
halt the cell cycle at the G2/M stage (Fig. 7).
Our findings suggest that cell cycle regulatory proteins may have played a major
role in the inhibitory effect of IAA treatment on MCF-7. As shown in both
microarray analysis and TUNEL assay however, IAA seems to exhibit
additional characteristics that induce apoptosis. Although 25 μg/ml IAA
treatment did not result in a statistically higher rate of apoptosis than 0 μg/ml
IAA treatment in TUNEL assay, 50 μg/ml IAA (p < 0.05) treatment triggered a
stronger apoptotic effect on MCF-7. As shown by the microarray results
(Table 1), up-regulated FAS or down-regulated BIRC5 may be involved in
apoptotic mechanisms. FAS expression was speculated to have been induced by
IAA treatment, just as UV-irradiation can cause apoptosis by activation of cell
surface death receptors like FAS [29]. It is also hypothesized that IAA treatment
induced apoptosis by down-regulating BIRC5, the smallest of the inhibitory
apoptosis proteins [30]. More in-depth molecular studies are required to
ascertain if apoptosis from enhanced FAS and/or BIRC5 expression is involved
in inhibition of MCF-7 cell growth.
Shown also in results of our microarray analysis, IAA treatment decreased
expression in eight breast cancer-related genes (KIF, PBK, KIAA1524, BRCA2,
TP73, TOP2A, SGOL, and HMMR). These genes are usually elevated in breast
tumors and function in carcinogenesis and metastasis ([31, 32, 33, 34, 35, 36,
37, 38], refer to Table 1 for gene descriptions).
In conclusion, our series of studies clearly indicate that IAA has anti-
carcinogenic effects on several human cancer cell lines, and cell proliferation
was greatly inhibited by IAA treatment in a dose-dependent manner. Our results
showed its application triggered molecular mechanisms that lead to increased
expression of BTG2, p21, and GADD45A, and decreased expression of CDK1
and cyclins B1and B2, changes which all resulted in G2/M cell cycle arrest.
These findings suggest that IAA has high potential for development as a new
anti-cancer drug through its inhibitory effect on cancer cell proliferation.
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